Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose: BCVA: loss of 15 or more ETDRS letters
Photodynamic therapy with verteporfin leads to lower loss of 3 or more lines (15 or more letters) visual acuity ETDRS chart compared with photodynamic therapy with 5% dextrose (high certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Photodynamic therapy with verteporfin vs photodynamic therapy with 5% dextrose Loss of 3 or more lines (15 or more letters) visual acuity ETDRS chart · patients with neovascular age‐related macular degeneration Photodynamic therapy with verteporfin leads to lower loss of 3 or more lines (15 or more letters) visual acuity ETDRS chart compared with photodynamic therapy with 5% dextrose (high certainty). Photodynamic therapy for neovascular age‐related macular degeneration (2007) · Cochrane Headline outcomes only | RR 0.8 [0.73, 0.88] | 4 studies · 1381 participants | High |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Photodynamic therapy for neovascular age‐related macular degeneration 2007 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.